{
      "brief_title": [
            "eva",
            "evista",
            "alendronate",
            "comparison"
      ],
      "brief_summary": [
            "purpose",
            "study",
            "determine",
            "treatment",
            "raloxifene",
            "compare",
            "treatment",
            "alendronate",
            "postmenopausal",
            "woman",
            "osteoporosis",
            "chance",
            "experience",
            "fracture"
      ],
      "condition": [],
      "intervention_type": [
            "Drug"
      ],
      "intervention_name": [
            "raloxifene HCI and alendronate Na"
      ],
      "criteria": [
            "inclusion",
            "criterion",
            "year",
            "age",
            "inclusive",
            "2",
            "year",
            "since",
            "last",
            "menses",
            "dx",
            "femoral",
            "neck",
            "osteoporosis",
            "vertebral",
            "fracture",
            "exclusion",
            "criterion",
            "poor",
            "candidate",
            "study",
            "drug",
            "hx",
            "disease",
            "affect",
            "bone",
            "metabolism",
            "hx",
            "cancer",
            "current",
            "use",
            "osteoporosis",
            "drug",
            "therapy",
            "risk",
            "vte"
      ],
      "gender": "Female",
      "minimum_age": [
            "50",
            "year"
      ],
      "maximum_age": [
            "80",
            "year"
      ],
      "healthy_volunteers": "No",
      "mesh_term": [
            "hydrochloride"
      ],
      "id": "NCT00035971"
}